Author/Authors :
Lee D. Jennings، نويسنده , , Derek C. Cole، نويسنده , , Joseph R. Stock، نويسنده , , Mohani N. Sukhdeo، نويسنده , , John W. Ellingboe، نويسنده , , Rebecca Cowling، نويسنده , , Guixian Jin، نويسنده , , Eric S. Manas، نويسنده , , Kristi Y. Fan، نويسنده , , Michael S. Malamas، نويسنده , , Boyd L. Harrison، نويسنده , , Steve Jacobsen، نويسنده , , Rajiv Chopra، نويسنده , , Peter A. Lohse، نويسنده , , William J. Moore، نويسنده , , Mary-Margaret O’Donnell، نويسنده , , Yun Hu، نويسنده , , Albert J. Robichaud، نويسنده , , M. James Turner، نويسنده , , Erik Wagner، نويسنده , , et al.، نويسنده ,
Abstract :
The proteolytic enzyme β-secretase (BACE-1) produces amyloid β (Aβ) peptide, the primary constituent of neurofibrillary plaques, implicated in Alzheimer’s disease, by cleavage of the amyloid precursor protein. A small molecule inhibitor of BACE-1, (diaminomethylene)-2,5-diphenyl-1H-pyrrole-1-acetamide (1, BACE-1 IC50 = 3.7 μM), was recently described, representing a new small molecule lead. Initial SAR investigation demonstrated the potential of accessing the nearby S3 and substrate binding pockets of the BACE-1 enzyme by building substituents off one of the phenyl substituents and guanidinyl functional group. We report here the optimization of guanidinyl functional group substituents on 1, leading to potent submicromolar BACE-1 inhibitors.
Keywords :
amyloid peptide , BACE-1 , Aspartyl protease inhibitor , A? peptide , BACE-1 inhibitor , Alzheimer’s disease